Docetaxel Plus Capecitabine in Newly Diagnosed Localized or Locally Advanced Prostate Cancer
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
Purpose: The purpose of this clinical trial is to look at the chemotherapy combination of
docetaxel and capecitabine in the treatment of newly diagnosed or locally advanced prostate
cancer, and to determine if this treatment is an acceptable, effective and a safe treatment
option. In addition, this clinical trial will evaluate how this treatment affects chemicals
(enzymes), and other cancer related genetic changes in the tumor. Optional: This clinical
trial will conduct extra imaging studies for research purposes including combined endorectal
prostate magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRSI) and
diffusion weighted imaging (DWI) to evaluate prostate cancer and response to study treatment.
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center